or Try an Advanced Search...

    Technical Analysis for MORF - Morphic Holding, Inc.

    Grade Last Price % Change Price Change
    F 30.12 -0.76% -0.23
    MORF closed down 0.76 percent on Tuesday, May 7, 2024, on 1.18 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Up
    Historical MORF trend table...
    Date Alert Name Type % Chg
    Bollinger Band Squeeze Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    Multiple of Ten Bullish Other 0.00%
    Weak + Overbought Other 0.00%
    BB Squeeze + Upper Band Touch Range Contraction 0.00%
    BB Squeeze Started Range Contraction 0.00%
    Weak, Overbought and Reversal Signs Reversal 0.00%
    Overbought Stochastic Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    New Uptrend Bullish -0.76%
    Older End-of-Day Signals for MORF ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 17 hours ago
    Possible Pocket Pivot about 18 hours ago
    Down 1% about 20 hours ago
    2x Volume Pace about 20 hours ago
    1.5x Volume Pace about 20 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    MORF Chart by TradingView
    Basic chart:

    Profile

    Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Clinical Development Molecular Biology Gastrointestinal Inflammatory Bowel Disease Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Fibrosis Gastrointestinal Cancer Treatment Of Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Inflammatory Bowel Disease Integrin

    Is MORF a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 1 Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation
    Apr 26 Morphic Holding files automatic mixed shelf
    Apr 25 Morphic Holding Inc (MORF) Q1 2024 Earnings: A Detailed Review
    Apr 25 Morphic GAAP EPS of -$0.91
    Apr 25 Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
    Apr 24 What Makes Morphic (MORF) a New Buy Stock
    Mar 21 Morphic Holding Insiders Placed Bullish Bets Worth US$47.3m
    Mar 19 Morphic appoints Simon Cooper as CMO
    Mar 19 Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
    Mar 5 Morphic to Participate in March Investor Conferences
    See more MORF news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 63.0825
    52 Week Low 19.345
    Average Volume 406,433
    200-Day Moving Average 34.17
    50-Day Moving Average 32.17
    20-Day Moving Average 28.65
    10-Day Moving Average 28.60
    Average True Range 1.34
    RSI (14) 52.15
    ADX 27.59
    +DI 21.73
    -DI 20.10
    Chandelier Exit (Long, 3 ATRs) 26.75
    Chandelier Exit (Short, 3 ATRs) 30.38
    Upper Bollinger Bands 30.63
    Lower Bollinger Band 26.67
    Percent B (%b) 0.87
    BandWidth 13.79
    MACD Line -0.63
    MACD Signal Line -1.11
    MACD Histogram 0.4751
    Fundamentals Value
    Market Cap 1.5 Billion
    Num Shares 49.7 Million
    EPS -3.29
    Price-to-Earnings (P/E) Ratio -9.16
    Price-to-Sales 296.69
    Price-to-Book 2.73
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 31.25
    Resistance 3 (R3) 31.32 31.03 31.06
    Resistance 2 (R2) 31.03 30.74 30.99 30.99
    Resistance 1 (R1) 30.57 30.56 30.43 30.50 30.93
    Pivot Point 30.28 30.28 30.20 30.24 30.28
    Support 1 (S1) 29.82 29.99 29.68 29.75 29.31
    Support 2 (S2) 29.53 29.81 29.49 29.25
    Support 3 (S3) 29.07 29.53 29.18
    Support 4 (S4) 29.00